|
Article Excerpt
M2 PRESSWIRE-31 August 2007-BUYINS.NET: (ARNA) SqueezeTrigger Price is $12.941. There is $143,865,129.00 That Short Sellers Still Need To Cover(C)1994-2007 M2 COMMUNICATIONS LTD
RDATE:31082007
BUYINS.NET / www.squeezetrigger.com is monitoring ARENA PHARMACEUTI (NASDAQ:ARNA) in real time and just received an alert that is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 10923700 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $12.941. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
From January 2005 to July 2007, an aggregate amount of 118737262 shares of ARNA have been shorted for a total dollar value of $1,424,847,144.00. The ARNA SqueezeTrigger price of $12.941 is the volume weighted average price that all shorts are short in shares of ARNA. There is still approximately $143,865,129.00 of potential short covering in shares of ARNA.
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .
ARENA PHARMACEUTI (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc. (Arena), incorporated in April 1997, is a clinical-stage biopharmaceutical company focusing on the discovery, development and commercialization of small molecule drugs targeting G protein-coupled receptors (GPCR), in four major therapeutic areas, metabolic, central nervous system, cardiovascular and inflammatory diseases. Its drug candidates act on or through known and orphan GPCRs. Arena completed a 469-patient, 12-week Phase IIb clinical trial of APD356, which demonstrated statistically significant weight loss versus placebo at all three doses studied. Its lead drug candidate...
|
|
More articles from M2 Presswire
(GHL) SqueezeTrigger Price is $58.410. There is $351,168,036.00 That S..., August 31, 2007
(KIM) SqueezeTrigger Price is $41.966. There is $337,224,750.00 That S..., August 31, 2007
Open Text Reports Fourth Quarter and Year-End 2007 Financial Results; ..., August 31, 2007
The Robinhood of the Debts., August 31, 2007
PETA Urges GAA to Implement Policy Barring Animal Abusers From Playing..., August 31, 2007
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
|
